<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.86090</article-id><article-id pub-id-type="publisher-id">ACM-26316</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180600000_31765132.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  NLRP3炎性小体与系统性红斑狼疮的相关研究
  Related Research on NLRP3 Inflammasome and SLE
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>嘉妮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曹</surname><given-names>慧琴</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>宇宏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院免疫风湿科，陕西 延安</addr-line></aff><aff id="aff3"><addr-line>延安大学附属医院血液免疫科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>07</month><year>2018</year></pub-date><volume>08</volume><issue>06</issue><fpage>544</fpage><lpage>548</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    核苷酸结合寡聚化结构域样受体3 (NLRP3)，是胞质型模式识别受体NOD样受体(pyrin domain con-taining, NLR)家族的一员，属于NLR家族中的一个典型代表。NLRP3炎性小体能活化胱天蛋白酶(caspase-1)，进一步剪切IL-1β、IL-18前体，使其成为有活性的促炎因子再释放，来参与机体抵抗病原体的免疫应答。近来研究发现，系性红斑狼疮(SLE)患者血清IL-1β、IL-18水平升高，且与SLE严重程度密切相关。本文综述了NLRP3的结构、激活方式及与SLE疾病的研究进展，为寻求更精准的靶向治疗途径作参考。
    NLRP3 is one of the members of NOD and belongs to a typical representative in NLR family. In-flammasome of NLRP3 is able to activate caspase-1 and further shears IL-1β, IL-18 precusor, to make them active proinflammatory factor which will be released in order to participate in the immune response in organism’s resistance to pathogene. Recent researches showed that SLE pa-tients’ serum levels of IL-1β and IL-18 about SLE patients were elevated and these levels are closely related to the severity of SLE. This article summarizes the structure and activation method of NLRP3 as well as its research progress with SLE so as to search for more accurate targeted therapy approach which can be a reference. 
  
 
</p></abstract><kwd-group><kwd>炎性小体，SLE疾病，综述, Inflammasome</kwd><kwd> SLE Disease</kwd><kwd> Summary</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>NLRP3炎性小体与系统性红斑狼疮的相关研究<sup> </sup></title><p>王嘉妮<sup>1</sup>，曹慧琴<sup>2</sup>，刘宇宏<sup>1*</sup></p><p><sup>1</sup>延安大学附属医院免疫风湿科，陕西 延安</p><p><sup>2</sup>延安大学附属医院血液免疫科，陕西 延安</p><disp-formula id="hanspub.26316-formula41"><graphic xlink:href="//html.hanspub.org/file/7-1570640x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年7月12日；录用日期：2018年8月2日；发布日期：2018年8月9日</p><disp-formula id="hanspub.26316-formula42"><graphic xlink:href="//html.hanspub.org/file/7-1570640x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>核苷酸结合寡聚化结构域样受体3 (NLRP3)，是胞质型模式识别受体NOD样受体(pyrin domain containing, NLR)家族的一员，属于NLR家族中的一个典型代表。NLRP3炎性小体能活化胱天蛋白酶(caspase-1)，进一步剪切IL-1β、IL-18前体，使其成为有活性的促炎因子再释放，来参与机体抵抗病原体的免疫应答。近来研究发现，系性红斑狼疮(SLE)患者血清IL-1β、IL-18水平升高，且与SLE严重程度密切相关。本文综述了NLRP3的结构、激活方式及与SLE疾病的研究进展，为寻求更精准的靶向治疗途径作参考。</p><p>关键词 :炎性小体，SLE疾病，综述</p><disp-formula id="hanspub.26316-formula43"><graphic xlink:href="//html.hanspub.org/file/7-1570640x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/7-1570640x8_hanspub.png" /> <img src="//html.hanspub.org/file/7-1570640x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>系统性红斑狼疮(systemic lupus erythematosus, SLE)是一累积多系统、多脏器的具有多种自身抗体及免疫复合物形成的自身免疫性疾病，可引起皮肤、血液、肾脏、神经系统等多系统损害 [<xref ref-type="bibr" rid="hanspub.26316-ref1">1</xref>] 。狼疮肾炎(Lupus Nephritis, LN)是SLE最常见和最严重的临床表现，神经精神性狼疮(Neuropsychiatric systemic lupus erythematosus, NPSLE)是SLE较严重的表现，其临床表现严重、预后差、病死率高，且缺乏有效的临床检查方法，致其诊断和治疗困难 [<xref ref-type="bibr" rid="hanspub.26316-ref2">2</xref>] 。岂今，SLE的病因和发病机制尚不明确，目前所认为其发病是遗传因素、激素、感染、环境、药物、自身免疫系统异常活化等多种因素共同作用于机体产生的异常炎症性免疫反应。近年来，对于研究的不断深层探索，炎症小体在调节炎症性免疫反应中的作用逐渐突出，且受到重视。因此，通过了解NLRP3炎性体激活的调控，从而发展有效的治疗方法来对抗一系列的炎症性疾病，诸如SLE，本文将对NLRP3炎性体在SLE炎症中的作用作一综述。</p></sec><sec id="s4"><title>2. NLRP3炎性小体的结构和激活方式</title><sec id="s4_1"><title>2.1. 炎性小体的组成、功能</title><p>NLRP3炎性小体(inflammasome)是由识别分子NLRP3，凋亡相关点状蛋白ASC和胱天蛋白酶1前体pro-caspase-1组装成的多聚体蛋白复合物，分子量约700 Kda，主要表达于中性粒细胞、单核细胞、巨噬细胞和树突状细胞内 [<xref ref-type="bibr" rid="hanspub.26316-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.26316-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.26316-ref5">5</xref>] 。核心蛋白NLRP3分三部分：① c-末端的亮氨酸重复序列LRR：负责感知和识别PAMPs (病原体相关的分子模式)和DAMPs (损伤相关的分子模式)；② 中央的核苷酸结合域NACTH：负责介导NLR寡聚化并形成炎性小体的核心结构；③ 氨基末端的热蛋白结构域PYD亦称为CARD (caspase recruitment domain)或BIR (baculovirus inhibitor repeats)：负责信号转导作用。桥接蛋白ASC具有两部分结构：PYD负责与NLRP3的PYD-PYD连接，使NLRP3与适配器ASC形成了一个炎症体；CARD负责招募pro-caspase-1，即可将NLRP3、ASC、pro-caspase-1三者连接起来，导致caspase-1激活，释放促炎细胞因子和细胞死亡 [<xref ref-type="bibr" rid="hanspub.26316-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.26316-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.26316-ref8">8</xref>] 。</p></sec><sec id="s4_2"><title>2.2. NLRP3炎性小体的激活机制</title><p>有关NLRP3炎性小体的激活通路存在较多的争议，以下3种说法最为被认可：</p><p>1) 三磷酸腺苷(ATP)-门控离子通道(P2X7)：单核细胞、巨噬细胞和树突状细胞(DCs)是IL-1β的主要来源。在单核细胞、巨噬细胞和树突状细胞(DCs)中，ATP流入细胞外间隙后，ATP门控离子通道嘌呤7 (P2X7)随及通过连接蛋白、泛连接蛋白半通道、阴离子通道及溶酶体胞外分泌等的作用而被活化。活化的ATP门控离子通道嘌呤7(P2X7)促使IL-1β大量生成，从而引起下游NLRP3炎症小体的活化 [<xref ref-type="bibr" rid="hanspub.26316-ref9">9</xref>] 。</p><p>2) 溶酶体失稳和破裂：事实上，不同的PAMPs和DAMPs似乎都依赖于溶酶体的失稳来触发NLRP3炎症激活。这些DAMPs包括细菌微生物信号、真菌、核酸、细菌造孔毒素(如尼日利亚菌素)，环境刺激物(如石棉、二氧化硅、明矾或紫外线)，内源性危险信号(如，胞外ATP、尿酸盐(MSU)晶体、β淀粉样沉淀、透明质酸、肽聚集) [<xref ref-type="bibr" rid="hanspub.26316-ref10">10</xref>] 。颗粒性物质和病原体的吞噬作用或者无菌溶酶体的损伤均可破坏溶酶体膜的结构，从而激活NLRP3。例如，腺病毒穿过核内体膜，使溶酶体膜破坏和组织蛋白酶B释放，从而激活NLRP3。在蛋白酶B或L缺乏的小鼠中，胆固醇晶体诱导的IL-1β释放减少。尼日利亚菌可使线粒体ROS生成，进而导致溶酶体膜的透化作用，进而激活NLRP3炎性体 [<xref ref-type="bibr" rid="hanspub.26316-ref11">11</xref>] 。以上举例足以证明溶酶体破坏对于NLRP3激活的重要性。</p><p>3) 线粒体活性氧(ROS)的产生：NLRP3激活所需的ROS是由线粒体产生的，所以线粒体是NLRP3炎性体激活的关键。线粒体ROS的释放可以导致溶酶体膜的浸透性(LMP)改变，但仍保持溶酶体酸度，缺乏NLRP3的巨噬细胞表现出线粒体功能减退和ATP损失的状态，证明LMP是NLRP3依赖的 [<xref ref-type="bibr" rid="hanspub.26316-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.26316-ref13">13</xref>] 。一些研究表明 [<xref ref-type="bibr" rid="hanspub.26316-ref13">13</xref>] ，离子通量引起线粒体功能障碍，也是NLRP3炎性体激活所需要的。细胞内钙的升高导致线粒体基质通过线粒体钙(MCU)摄取钙，摄取后线粒体功能紊乱，亦引起NLRP3的激活。事实上，许多NLRP3炎性体激活剂都被认为能在多种细胞中触发线粒体ROS产生。最近有研究表明，在NLRP3炎性体激活过程中，黄嘌呤氧化酶原ROS在巨噬细胞IL-1β释放和caspase-1分泌中起作用 [<xref ref-type="bibr" rid="hanspub.26316-ref11">11</xref>] 。在阐明ROS参与调控NLRP3炎症反应的过程中，虽已取得很多进展，但仍需更多有关机制的研究来了解不同来源的ROS如何调节炎性体激活。</p></sec></sec><sec id="s5"><title>3. NLRP3炎性小体与SLE</title><p>陈斯玲等 [<xref ref-type="bibr" rid="hanspub.26316-ref14">14</xref>] 对40例SLE患者和30例健康体检者进行了对照研究发现，与对照组相比，SLE患者IL-1β、IL-18血清水平较高；同时发现，血清IL-1β水平与浆膜炎、SLEDAI评分、血沉、LN呈正相关；血清IL-18水平与LN、SLEDAI评分、24 h尿蛋白呈正相关，活动期患者血清IL-1β和IL-18的水平较稳定期患者明显升高(p &lt; 0.05)。</p><p>Ailing Lu等 [<xref ref-type="bibr" rid="hanspub.26316-ref15">15</xref>] 利用姥鲛烷诱导的试验狼疮老鼠模型探讨了NLRP3在SLE发展中的作用，发现NLRP3-R258W突变小鼠出现更严重的狼疮样综合征，NLRP3-R258W突变小鼠在姥鲛烷诱导实验中的死亡率显著升高(p &lt; 0.05)。此外，NLRP3-R258W突变小鼠肾小球中可见明显的高细胞性和间质性肾炎。且该小鼠的NLRP3炎症因子的亢进导致了蛋白尿和系膜破坏。最近也有研究证实，在狼疮巨噬细胞中，中性粒细胞胞外捕集器(NETs)可以通过激活caspase-1，导致IL-1和IL-18的释放,这一激活又增强SLE患者的巨噬细胞，从而致病 [<xref ref-type="bibr" rid="hanspub.26316-ref16">16</xref>] 。综上所述，NLRP3炎症通路在SLE的发展中有关键作用，并提示抑制炎性体信号可能有助于控制狼疮的炎症损伤。</p><sec id="s5_1"><title>3.1. NLRP3炎性小体与LN</title><p>近来，许多研究表示，LN的发病过程离不开NLRP3介导的固有免疫反应，这一成果为我们更深入研究其详细发病机制和防治措施提供了新的思路和靶点。一些基础临床研究 [<xref ref-type="bibr" rid="hanspub.26316-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.26316-ref18">18</xref>] 发现，虽然NLRP3在LN患者中的作用机制尚不清楚，但LN患者的血清和肾小球的IL-18水平升高，这一指标与患者尿蛋白、肾组织病理改变、IGg类免疫复合物沉积呈正相关，而IL-18是属于NLRP3的下游炎症因子，进而推断NLRP3与LN的肾脏损伤程度有一定相关性，可以作为判断LN病情严重程度的指标。J. Michelle Kahlenberg等 [<xref ref-type="bibr" rid="hanspub.26316-ref19">19</xref>] 在试验中发现，caspase-1(−/−)小鼠可以通过姥鲛烷诱导模型来抵抗狼疮。与野生型小鼠相比，caspase-1(−/−)小鼠的抗ds-DNA和抗-RNA自身抗体滴度均显著降低，对肾脏免疫复合物沉积和肾脏炎症均有保护作用。也有学者在MRL lpr/lpr小鼠中观察到IL-1β基因表达增加，抑制MRL lpr/lpr小鼠的NLRP3炎性小体−IL-1β轴的表达，会减弱蛋白尿、自身抗体产生、全身促炎细胞因子和肾脏病理 [<xref ref-type="bibr" rid="hanspub.26316-ref20">20</xref>] 。上述研究结果显示，NLRP3可能在LN的疾病进展中起着重要的病理作用，尤其在肾小球病变的病理过程中。NLRP3可能是判断LN病情严重程度的一项指标。</p><p>狼疮性肾炎除累及肾小球外，还会累及肾小管间质和血管。且有间质或血管病变的患者肾脏受损往往较重。有学者研究 [<xref ref-type="bibr" rid="hanspub.26316-ref18">18</xref>] 得出结论，LN患者血清IL-18水平与肾小管上皮细胞变性、肾小管白细胞管型、肾小管炎症细胞浸润，肾间质纤维化呈正相关(p &lt; 0.05)。可以猜想，是否能够通过早期监测SLE患者血清IL-18和IL-1β水平，较早发现SLE患者有早期肾损伤危险因素，若已有肾损害患者可及时通过干扰NLRP3炎性体-IL-18轴/IL-1β轴，来减轻或控制炎症因子对于肾脏的损害程度，从而降低LN发展为肾衰竭及致死的发生。</p></sec><sec id="s5_2"><title>3.2. NLRP3炎性小体与NPSLE</title><p>NPSLE可出现在SLE病程中的任一阶段。可以是急性发病，也可以是慢性起病，精神症状出现较神经症状早。神经症状包括癫痫发作、狼疮头痛、脑出血、脑血栓、周围神经损害、双眼失明；精神症状含情感障碍、意识障碍、认知障碍。马晓莉等 [<xref ref-type="bibr" rid="hanspub.26316-ref21">21</xref>] 对60例NPSLE患者的临床表现进行回顾性研究，结果提示：NPSLE患者的临床表现中以癫痫发作出现几率最高(28.3%)，其次为狼疮头痛(23.3%)、意识障碍(18.3%) (p &lt; 0.05)。上述症状给患者带来极大的困扰和痛苦，因此，寻求新的治疗途径和方向是未来发展的必经之路。</p><p>王莉莉 [<xref ref-type="bibr" rid="hanspub.26316-ref22">22</xref>] 等人收集CNS-NPSLE、无CNS表现SLE (non-CNS SLE)和正常对照组的血清和脑脊液(CSF)，应用酶联免疫吸附法测定血清及CSF中IL-1β水平，得出结论：① CNS-NPSLE组血清、CSF中IL-1β水平均明显高于正常对照组；② CNS-NPSLE组CSF IL-1β水平均高于non-CNS SLE组；③CNS-NPSLE组CSF IL-1β水平均高于血清水平(p &lt; 0.05)。还有研究发现IL-1β诱导SLE患者和健康对照组的细胞产生IgG，在神经SLE患者CSF中还发现，IL-1β水平的升高是由SLE患者的B细胞产生的 [<xref ref-type="bibr" rid="hanspub.26316-ref23">23</xref>] 。更进一步证实了血清及CSF中IL-1β水平可能与CNS-NPSLE的发病有一定的关系。提示我们是否可以通过抑制这种炎症因子来防止器官损伤，达到靶向NLRP3炎症体治疗。</p></sec></sec><sec id="s6"><title>4. 小结</title><p>NLRP3炎性小体的研究，一直是各领域学者研究的热点之一。NLRP3与临床心血管、内分泌、呼吸、等多个系统甚至肿瘤疾病的发病机制均有关系 [<xref ref-type="bibr" rid="hanspub.26316-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.26316-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.26316-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.26316-ref27">27</xref>] 。在自身免疫性疾病方面，也已有了新的发现，尤其是对SLE疾病的研究，血清IL-1β和IL-18水平与SLE病情的活动、严重程度及靶器官的受损程度均呈正相关，亦发现狼疮肾炎、狼疮脑病、及皮肤狼疮与NLRP3介导的炎症因子有密不可分的关系。对于炎性体在SLE疾病中致病的具体作用和机制尚有待进一步研究，因此需要有更多的临床工作者来深入研究。可以猜想，对NLRP3致病的不断认识，SLE等自身免疫相关性疾病的靶向治疗也将指日可待。</p></sec><sec id="s7"><title>文章引用</title><p>王嘉妮,曹慧琴,刘宇宏. NLRP3炎性小体与系统性红斑狼疮的相关研究 Related Research on NLRP3 Inflammasome and SLE[J]. 临床医学进展, 2018, 08(06): 544-548. https://doi.org/10.12677/ACM.2018.86090</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.26316-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Dema, B. and Charles, N. (2014) Advances in Mechanisms of Systemic Lupus Erythematosus. Discovery Medicine, 17, 247-255.</mixed-citation></ref><ref id="hanspub.26316-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Q., Liu, J. and Wu, X.D. (2018) Clinical Study on Intrathecal Injection of Combined with Dexa-methasone for Treating Neuropsychiastric Systemic Lupus Erythematsus. China Pharmaceuticals, 27, 21-23.</mixed-citation></ref><ref id="hanspub.26316-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z.R., Meszaros, G., He, W.T., et al. (2017) Protein Kinase D at the Golgi controls NLRP3 In-flammasome Activation. Journal of Experimental Medicine, 214, 2671-2693. https://doi.org/10.1084/jem.20162040</mixed-citation></ref><ref id="hanspub.26316-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Till, S., Jorge, H.M., Eran, E., et al. (2012) Inflammasomes in Health and Disease. Nature, 481, 278-286.  
https://doi.org/10.1038/nature10759</mixed-citation></ref><ref id="hanspub.26316-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Guarda, G., Zenger, M., Yazdi, A.S., et al. (2011) Differential Expres-sion of NLRP3 among Hematopoietic Cells. Journal of Immunology, 186, 2529-2534. https://doi.org/10.4049/jimmunol.1002720</mixed-citation></ref><ref id="hanspub.26316-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Eun, K.J., Jin, K.K., Dong, M.S. and Chihiro, S. (2016) Molecular Mechanisms Regulating NLRP3 Inflammasome Activation. Cellular and Molecular Immunology, 13, 148-159. https://doi.org/10.1038/cmi.2015.95</mixed-citation></ref><ref id="hanspub.26316-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Bauernfeind, F. and Hornung, V. (2013) Of Inflammasomes and Path-ogens-Sensing of Microbes by the Inflammasome. EMBO Molecular Medicine, 5, 814 -826. https://doi.org/10.1002/emmm.201201771</mixed-citation></ref><ref id="hanspub.26316-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Stutz, A., Kolbe, C.C., Stahl, R., et al. (2017) NLRP3 Inflam-masome Assembly Is Regulated by Phosphorylation of the Pyrin Domain. Journal of Experimental Medicine, 214, 1725-1736. https://doi.org/10.1084/jem.20160933</mixed-citation></ref><ref id="hanspub.26316-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Asgari, E., Le Friec, G., Yamamoto, H., et al. (2013) C3a Modulates IL-1β Secretion in Human Monocytes by Regulating ATP Efflux and Subsequent NLRP3 Inflammasome Activation. Blood, 122, 3473-3481.  
https://doi.org/10.1182/blood-2013-05-502229</mixed-citation></ref><ref id="hanspub.26316-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Chul, S.Y., Dong, M.S. and Eun, K.J. (2012) The Role of NLR-Related Protein 3 Inflammasome in Host Defense and Inflammatory Diseases. International Neurourology Journal, 16, 2-12. https://doi.org/10.5213/inj.2012.16.1.2</mixed-citation></ref><ref id="hanspub.26316-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Jo, E.K., Kim, J.K., Shin, D.M., et al. (2016) Molecular Mechanisms Regulating NLRP3 Inflammasome Activation. Cellular &amp; Molecular Immunology, 13, 148-159. https://doi.org/10.1038/cmi.2015.95</mixed-citation></ref><ref id="hanspub.26316-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Heid, M.E., Keyel, P.A., Kamga, C., et al. (2013) Mitochondrial ROS Induces NLRP3-Dependent Lysosomal Damage and Inflammasome Activation. The Journal of Immunology, 191, 5230-5238.  
https://doi.org/10.4049/jimmunol.1301490</mixed-citation></ref><ref id="hanspub.26316-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sutterwala, F.S., Haasken, S. and Cassel, S.L. (2014) Mechanism of NLRP3 Inflammasome Activation. Annals of the New York Academy of Sciences, 1319, 82-95. https://doi.org/10.1111/nyas.12458</mixed-citation></ref><ref id="hanspub.26316-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">陈斯玲, 陶怡, 陈瑞林. 系统性红斑狼疮患者血清IL-1β和IL-18的表达及意义[J]. 广东医学, 2017, 38(16): 2473-2475.</mixed-citation></ref><ref id="hanspub.26316-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lu, A.L., Li, H., Niu, J.L., et al. (2017) Hyperactivation of the NLRP3 Inflammasome in Myeloid Cells Leads to Severe Organ Damage in Experimental Lupus. The Journal of Immunology, 198, 1119-1129.  
https://doi.org/10.4049/jimmunol.1600659</mixed-citation></ref><ref id="hanspub.26316-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kahlenberg, J.M. and Kaplan, M.J. (2014) The Inflammasome and Lupus: Another Innate Immune Mechanism Contributing to Disease Pathogenesis? Current Opinion in Rheumatology, 26, 475-481.  
https://doi.org/10.1097/BOR.0000000000000088</mixed-citation></ref><ref id="hanspub.26316-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, Y. and Liu, Z. (2015) Isoflurane Attenuates Murine Lupus Nephritis by Inhibiting NLRP3 Inflammasome Activation. International Journal of Clinical and Experimental Medicine, 8, 17730-17738.</mixed-citation></ref><ref id="hanspub.26316-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Meilan, L., Fuzhe, M., Hao, W., et al. (2018) Levels of Serum IL-18 and IL-34 in Pa-tients with Lupus Nephritis and Their Significance. China Journal of Modern Medicine, 28, 53-56.</mixed-citation></ref><ref id="hanspub.26316-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kahlenberg, J.M., Yalavarthi, S., Zhao, W., et al. (2014) An Essential Role for Caspase-1 in the Induction of Murine Lupus and Its Associated Vascular Damage. Arthritis &amp; Rheumatology, 66, 153-162. https://doi.org/10.1002/art.38225</mixed-citation></ref><ref id="hanspub.26316-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y.Y., Li, H.T., Lu, Y., et al. (2017) Protective Effects of Glycyr-rhizic Acid against Lupus Nephritis in MRL/lpr Mice. Journal of Southern Medical University, 37, 957-961.</mixed-citation></ref><ref id="hanspub.26316-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ma, X.L., Gong, Y., Zhu, H., et al. (2010) Analysis on Clinical Features and Curative Effect in Patients with Neuropsychiaric Systemic Lupus Erythematosus. Ningxia Medical Journal, 32, 134-136.</mixed-citation></ref><ref id="hanspub.26316-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L.L., Wang, J.B., Liang, H.D., et al. (2014) Role of IL-1β, IL-6, IL-8 and IFN-γ to CNS-NPSLE Pathogenesis. Chinese Journal of Immunology, 30, 247-251.</mixed-citation></ref><ref id="hanspub.26316-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Gottschalk, T.A., Tsantikos, E. and Hibbs, M.L. (2015) Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus. Frontiers in Immunology, 6, 550. https://doi.org/10.3389/fimmu.2015.00550</mixed-citation></ref><ref id="hanspub.26316-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Long, J.H., Yin, P.Z., Yun, L.C., et al. (2018) The Relationship between NLRP3 Inflammasome and Coronary Heart Disease. Chinese Journal of Arteriosclerosis, 26, 281-286.</mixed-citation></ref><ref id="hanspub.26316-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Yi, X.L., Jian, M., Yang, W., et al. (2018) Role of NLRP3 Inflammasome in Diabetic Nephropathy Inflammatory Mechanisms. Journal of Liaoning University of TCM, 20, 126-128.</mixed-citation></ref><ref id="hanspub.26316-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">刘一鹏, 欧宗兴. NLRP3炎性小体与呼吸系统疾病的关系[J]. 海南医学, 2018, 29(2): 224-226.</mixed-citation></ref><ref id="hanspub.26316-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">范慧敏, 胡容. 炎症小体在肿瘤中的双重作用[J]. 药物生物技术, 2017, 24(2): 155-158.</mixed-citation></ref></ref-list></back></article>